Use of polypeptides in the manufacture of products for preventing or treating skin damage disorders

A polypeptide, Pro-Ala-Ala-Glu-Pro-Val-Pro-Leu, addresses the slow healing issues of chronic wounds by enhancing cell proliferation and vascular regeneration, offering faster absorption and better stability than existing treatments, effectively treating chronic intractable wounds and skin diseases.

JP2024543702AActive Publication Date: 2024-11-21SICHUAN GOODDOCTOR PANXI PHARMA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024536240
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-29
Filing Date
2022-12-29
Publication Date
2024-11-21
Estimated Expiration
2042-12-29

AI Technical Summary

Technical Problem

Current treatments for chronic intractable wounds and skin diseases, such as diabetic foot ulcers and vascular ulcers, are slow and have limited therapeutic efficacy, particularly due to slow absorption and stability issues with existing drugs like recombinant human epidermal growth factor.

Method used

Application of a polypeptide, specifically Pro-Ala-Ala-Glu-Pro-Val-Pro-Leu or its physiologically compatible salts, topically administered to promote wound healing by enhancing cell proliferation and vascular regeneration, including use in topical formulations like solutions, emulsions, gels, creams, sprays, masks, or dressings.

Benefits of technology

The polypeptide demonstrates faster skin absorption and better stability, promoting wound healing in chronic intractable wounds and acute skin diseases by inducing dedifferentiated cells to regain stem cell morphology and functionality, outperforming recombinant human epidermal growth factor in healing rates and efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543702000008
    Figure 2024543702000008
  • Figure 2024543702000009
    Figure 2024543702000009
  • Figure 2024543702000010
    Figure 2024543702000010
Patent Text Reader

Abstract

The invention provides the use of a polypeptide which is Pro-Ala-Ala-Glu-Pro-Val-Pro-Leu or a physiologically compatible salt thereof in the manufacture of a product for the prevention or treatment of skin lesions.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the application of a polypeptide in the manufacture of a product for preventing or treating skin damage diseases, and the polypeptide of the present invention has a remarkable effect of preventing and / or treating skin damage diseases, in particular chronic intractable wounds on the body surface, and acute and / or chronic skin diseases. [Background technology]

[0002] Human skin is composed of epithelium, dermis, and subcutaneous tissue, and includes accessory organs (sweat glands, sebaceous glands) and blood vessels, lymphatic vessels, nerves, and muscles. Skin is the outermost organ of the human body, the largest organ in the human body, and the organ that comes into most frequent and closest contact with the outside world. It covers the surface of the human body, protects the body to resist external insults, regulates body temperature, and also has a sensory function, and plays an important role in maintaining human health, so the skin is called the first line of defense for the human body. Because the skin covers the surface of the human body, it is susceptible to external damage, chemical irritation, and microbial infection. Skin damage refers to the expression of abnormalities seen or touched on the skin and mucous membranes. Skin damage can cause a double blow to the patient, both mentally and physically.

[0003] In recent years, chronic intractable wound diseases on the body surface have attracted attention among diseases caused by skin damage. Chronic intractable wounds on the body surface are also called intractable ulcers and are common intractable diseases. Local tissue defects, liquefaction, infection, and necrosis caused by various causes cause endothelial progenitor cell proliferation disorders, leading to vascular regeneration disorders, insufficient wound perfusion, metabolic disorders, and delayed epithelial cell formation, which destroy the normal wound healing process and form chronic ulcers.

[0004] Chronic wounds on the surface of the body are common complications of diabetes, peripheral vascular disease, and radiotherapy. The International Wound Healing Society defines them as wounds that cannot reach an anatomically and functionally intact state through the normal orderly and timely repair process. Clinically, they often refer to wounds formed by various causes that do not heal even after more than one month of formal treatment and have no obvious tendency to heal. Wound healing goes through three stages: (1) the inflammatory stage, (2) the proliferation stage, and (3) the maturation and heavy construction stage. Chronic wounds are characterized by prolonged inflammation, which inhibits the proliferation of vascular endothelial cells and fibroblasts and the deposition of collagen matrix.

[0005] Common chronic intractable wounds include diabetic foot ulcers, pressure ulcers, vascular ulcers, neurodystrophic ulcers, infectious ulcers, wound ulcers, autoimmune ulcers, cancer ulcers, and radiation ulcers. The incidence of these wounds increases with age, and the pathogenic mechanisms are complex and the disease course is relatively long.

[0006] Diabetic foot ulcers are mainly caused by nerve and blood vessel lesions due to the underlying diabetic disease, which leads to skin tissue ischemic necrosis or skin tissue infection, or the skin is broken by pressure at the support point, resulting in incomplete skin, exposing subcutaneous fat, muscle tissue, and even bone, and forming an ulcer. The damage caused by diabetic foot ulcers can cause itching, lack of sweating, dryness, pigmentation, mild foot pain, hypoesthesia, intermittent claudication, joint deformation, and skin surface ulcers in mild cases, and infection in relatively deep ulcers in moderate cases, and bones can be affected in severe cases, leading to fractures and bone necrosis, and in more severe cases, amputation may be required. Diabetic foot ulcers are one of the important causes of disability and even death in diabetic patients, and not only cause pain to patients, but also add a large economic burden. Currently, diabetic foot ulcers are often treated by controlling the primary disease, but because the treatment process is relatively slow, local ulcers are prone to infection during the treatment process, leading to serious consequences.

[0007] Pressure ulcers occur when pressure on local tissues of the body or blood circulation disorders cause local skin ischemia, hypoxia, and nutritional deficiency, causing the skin to lose its normal function and causing tissue damage and necrosis. They often occur on bony prominences such as the sacrococcygeal region, occipital region, and foot region of bedridden elderly patients. These areas have little soft tissue and weak resistance to pressure, and ulcers may develop when they are immobilized and compressed for a long time. Pressure ulcers not only cause pain to patients and delay recovery from illness, but in severe cases they can be life-threatening due to secondary infection and sepsis.

[0008] Vascular ulcers are ulcers of the lower limbs caused by varicose veins and vasculitis. They are most commonly seen in the distal parts of the lower limbs and the ankles, and are a late complication of chronic lower limb dysfunction. Severe blockage of venous return leads to increased local venous pressure and edema, which causes oxygen diffusion disorder and nutritional deficiency of the skin. Patients have a long history of primary venous disease, and the wound is usually single and relatively superficial, with a dark base of the wound, rough skin around the wound, and obvious pigmentation. The local skin temperature is very low. Regular changes of wound dressings have a poor therapeutic effect, and even split skin grafting has a very unreliable therapeutic effect.

[0009] Current research has found that skin wound repair is a complex process in which multiple factors such as keratinocytes, fibroblasts, vascular endothelial cells, inflammatory cells, extracellular matrix, cellular factors and growth factors are commonly involved, highly coordinated and mutually controlled. Currently, commonly used drugs for preventing or treating skin damage diseases include recombinant human epidermal growth factor, etc., which have certain preventive and / or therapeutic effects, but still have the defects of relatively slow absorption, relatively long treatment cycle, and unclear therapeutic effect, especially when applied to chronic intractable wounds on the body surface and acute and / or chronic skin diseases, there is little therapeutic effect. Summary of the Invention [Problem to be solved by the invention]

[0010] To overcome the shortcomings and deficiencies of the prior art, the object of the present invention is to provide an application of a polypeptide in the manufacture of a product for preventing or treating skin damage diseases. [Means for solving the problem]

[0011] According to a first aspect, the present invention provides the use of a polypeptide in the manufacture of a product for preventing or treating a skin damage disease, wherein the polypeptide is Pro-Ala-Ala-Glu-Pro-Val-Pro-Leu or a physiologically compatible salt thereof; or a method for preventing or treating a skin damage disease, said method comprising topically administering to a site of skin damage a product comprising Pro-Ala-Ala-Glu-Pro-Val-Pro-Leu or a physiologically compatible salt thereof; or a product comprising Pro-Ala-Ala-Glu-Pro-Val-Pro-Leu or a physiologically compatible salt thereof for use in preventing or treating a skin damage disease.

[0012] Further, skin damage diseases include wounds, ulcers, dermatitis, eczema, urticaria, polymorphous light eruption, herpes, acne, impetigo, melasma, vitiligo, lupus erythematosus, dermatomyositis, scleroderma, folliculitis, scabies, onychomycosis, chickenpox, infantile rash, warts, carbuncles, boils or ringworm. Further, dermatitis includes atopic dermatitis, contact dermatitis, neurodermatitis, seborrheic dermatitis, hormone-dependent dermatitis or stasis dermatitis. Additionally, wounds include chronic non-healing wounds on the surface of the body. Furthermore, chronic non-healing wounds on the body surface include diabetic foot ulcers, pressure ulcers, vascular ulcers and infected ulcers.

[0013] Further, the product may include a drug, a skin care product, or a cosmetic product. Furthermore, the product is a topical formulation. Additionally, the dosage form of the topical preparation includes a solution, emulsion, gel, cream, spray, mask or dressing.

[0014] Furthermore, the polypeptide exerts a proliferation promoting effect on human immortalized keratinocytes, human microvascular endothelial cells, fibroblasts, glial cells, and tissue and / or vascular regeneration, thereby healing wounds. Furthermore, the physiologically compatible salts refer to salt forms that are physiologically compatible (i.e., pharmacologically acceptable) and essentially non-toxic to individuals to whom the compounds of the present invention are administered. The physiologically compatible salts of the compounds of the present invention include conventional stoichiometric acid addition salts or base addition salts formed from suitable non-toxic organic or inorganic acids or inorganic bases.

[0015] The beneficial effects of the application of the polypeptide provided by the present invention in the manufacture of products for preventing or treating skin wound diseases, especially chronic intractable wounds on the body surface, are as follows:

[0016] The polypeptide described in the present invention not only has obvious wound healing promoting effect on skin ulcers and wounds compared with recombinant human epidermal growth factor, which is often used in the treatment of skin injury diseases in the prior art, but also has faster and better dermal absorption due to the short peptide chain of the present invention, excellent stability both in vivo and in vitro, and has a significant proliferation promoting effect on human immortalized keratinocytes, human microvascular endothelial cells, fibroblasts, neuroglial cells, and tissue and vascular regeneration, so that it has a significant preventive and / or therapeutic effect on acute and / or chronic skin diseases and chronic intractable wounds on the body surface (diabetic foot ulcer, decubitus ulcer, vascular ulcer, and infectious ulcer). The polypeptide described in the present invention can be applied to the manufacture of products for preventing or treating skin injury diseases, and can induce dedifferentiation of cells near the injury, and the dedifferentiated cells can regain stem cell morphology and cell division ability to form new units for repairing the injured wound, thereby exerting positive therapeutic and preventive effects. [Brief description of the drawings]

[0017] [Figure 1] 1 shows the promotion of proliferation of HaCaT cell line by polypeptides. [Diagram 2] 1 shows the promotion of proliferation of the HMEC-1 cell line by polypeptides. [Diagram 3]1 shows the promotion of proliferation of Balb-3T3 cell line by polypeptides. [Figure 4] 1 shows the promotion of proliferation of the RSC96 cell line by polypeptides. [Diagram 5] 1 shows the effect of polypeptides on zebrafish caudal fin regeneration. [Figure 6] 1 shows the effect of polypeptide on the revascularization area in zebrafish with microvascular loss. [Figure 7] 1 shows the effect of polypeptide-induced microvascular deletion on the number of revascularized branches in zebrafish. [Figure 8] 1 shows the rate of new granulation tissue formation by polypeptides on day 3 after injury in STZ-induced diabetic rats. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The present invention will be described below in combination with specific tests, but is not intended to limit the scope of the present invention. EXAMPLES

[0019] Example 1: Chemical synthesis of polypeptides The synthesis of the polypeptides used conventional solid-phase synthesis methods and involved multiple cyclic processes of resin swelling, substitution, deprotection, washing, amino acid dissolution, amino acid activation and condensation processes, washing, re-deprotection, and final degradation and side-chain deprotection.

[0020] Abbreviations: HBTU stands for benzotriazole-N,N,N',N'-tetramethylurea hexafluorophosphate, Methanol stands for methanol, Tert-Butyl methyl ether stands for methyl tert-butyl ether, Ethanol stands for ethanol, AA stands for amino acid, Cl-2-Cl-Resin stands for 2-chlorotrityl chloride resin, Fmoc-Aa(n) etc. stands for 9-fluorenylmethoxycarbonyl amino acid, DIPEA stands for N,N-diisopropylethylamine, DCM stands for dichloromethane, PIP stands for piperidine, DMF stands for N,N-dimethylformamide, HOBt stands for 1-hydroxybenzotriazole, DIC stands for N,N'-diisopropylcarbodiimide, TFA stands for trifluoroacetic acid, and TIPS stands for triisopropylsilane.

[0021] The method for synthesis and purification of the polypeptide is as follows. Step 1, Preparation of fully protected peptide resin (1) Swelling of resin: 2.0192 g (S=0.73 mmol / g) of 2-chlorotriyl chloride resin was weighed out and added to a synthesis tube equipped with a sieve plate, and the resin was swelled in 40 ml of dichloromethane for 30 minutes, and then the dichloromethane was removed by suction filtration. (2) Preparation of Fmoc-Asp(OtBu)-resin: Resin, Fmoc-Asp(OtBu)-OH, and DIPEA were weighed out in a molar ratio of 1:1.5:1.65, dissolved in 20 ml of dichloromethane, and added to a synthesis tube. The mixture was shaken at room temperature for 1-3 hours with N2 bubbles, and 2 ml of methanol was added directly to the reaction solution for blocking for 30 min. The mixture was then washed 4 times with 25 ml of dimethylformamide each time, and the resin was dried by suction.

[0022] (3) Removal of Fmoc protecting group: 20 ml of 20% piperidine-DMF (v / v) solution was added to the reaction apparatus, and reacted for 20 min with N2 bubble. The reaction was then dried by suction, washed 6 times with 25 ml of dimethylformamide for 3 min each time, dried by suction, and the Fmoc removal result was detected by the ninhydrin method. (4) Preactivation of amino acids: 4.38 mmol of Fmoc-protected amino acid, 5.26 mmol of HOBt, and 4.60 mmol of DIC were added to a 250 mL round-bottom flask, dissolved in 20 mL of 1:1 DCM-DMF (v / v), and preactivated for 30 to 60 min with stirring in an ice bath at -5 to 0 °C.

[0023] (5) Amino acid binding: The already activated protected amino acid solution was poured into the reactor and supplemented with an appropriate amount of DCM cleaning agent. The reaction was carried out at room temperature with N2 bubbling for 1-3 hours, and the amino acid binding was detected by the ninhydrin method to see if it was complete. If it was complete, it was sucked dry. The resin was washed with dimethylformamide 25ml / time, 3min / time, 4 times, and sucked dry. The dosage of each amino acid, condensation agent and specific reaction time are shown in Table 1. (6) After the first amino acid condensation was completed, steps (3) to (5) were repeated to extend the peptide chain in the order of amino acids until the coupling of the last amino acid was completed. (7) The resin peptide was washed six times with dichloromethane at 25 ml per wash for 3 min each wash, and then dried by suction.

[0024] [Table 1]

[0025] Step 2, cleavage and deprotection (1) To the synthesis tube of step 1, 50 ml of cleavage agent (TFA:TIPS:H2O = 95:2.5:2.5, v / v) was added, and the reaction was carried out for 1.5 to 3 hours by bubbling with N2. (2) After the completion of the cleavage reaction, the cleavage agent was suction filtered into a 250 ml round-bottom flask. After vacuum concentration to one-third of the original volume of the cleavage agent, 10 times the existing volume of methyl tert-butyl ether was added and stirred for 30 min. The resulting mixed solvent was filtered and washed three times with 30 ml of methyl tert-butyl ether, and the resulting crude peptide was placed in a sand core funnel and dried by blowing with N2 in a draft, and the solvent was volatilized so that the crude peptide became powdery.

[0026] Step 3, purification (salt exchange) and lyophilization The crude peptide obtained in step 2 was purified by HPLC using the following chromatography parameter condition A. Specifically, the crude peptide obtained in step 2 was dissolved in water and / or acetonitrile, filtered through a 0.45 μm filter membrane, injected, and gradient eluted with an acetonitrile-water mobile phase, and the target peptide eluate was collected and finally concentrated by rotary evaporation.

[0027] Chromatographic parameters Condition A: Chromatography column: YMC-Actus Triart C18 30*250mm, Eluent A: 0.1% (v / v) TFA / H2O, Eluent B: acetonitrile, Flow rate: 25ml / min, UV detection wavelength: 220nm.

[0028] [Table 2]

[0029] Then, the product obtained in the above step was salt-exchanged by HPLC using the following chromatography parameter condition B. A 95% A1+5% B equilibration chromatography column was used, followed by injection, then a 95% A2+5% B equilibration chromatography column was used, followed by gradient elution with A1 and B, the target peptide eluate was collected, and finally concentrated by rotary evaporation and lyophilized to obtain the polypeptide. The structure of the polypeptide was determined by MS,1 Confirmed by H-NMR.

[0030] Chromatographic parameters Condition B: Chromatography column: YMC-Actus Triart C18 30*250mm Eluent A1: 0.1M acetic acid Eluent A2: 0.025M acetic acid + 0.1M ammonium acetate Eluent B: Acetonitrile Flow rate: 25ml / min UV detection wavelength: 220nm

[0031] [Table 3]

[0032] Polypeptide 1 H-NMR is as follows: 1H NMR (600MHz, DMSO) δ8.25(s, 1H), 8.09(d, J=7.5Hz, 1H), 7.94(d, J=7.6Hz, 1H), 7.89(d, J=8.3Hz, 2 H), 4.53-4.46(m, 1H), 4.39(dd, J=8.3, 4.2Hz, 1H), 4.34(dd, J=8.4, 3.8Hz, 1H), 4.31-4.19(m, 3H) , 4.13(dd, J=15.1, 7.7Hz, 1H), 3.71-3.49(m, 5H), 2.94-2.77(m, 2H), 2.33-2.20(m, 2H), 2.06-1.7 7(m, 13H, AcOH), 1.77-1.56(m, 6H), 1.46(t, J=7.3Hz, 2H), 1.25-1.11(m, 6H), 0.95-0.76(m, 12H).

[0033] Polypeptide MS: 793.4, 397.3 (double charge). The amino acid sequence of the polypeptide is: Pro-Ala-Ala-Glu-Pro-Val-Pro-Leu. The following materials were used in the examples of this application:

[0034] Polypeptides, unless otherwise specified, i.e. the amino acid sequence is Pro-Ala-Ala-Glu-Pro-Val-Pro-Leu. Kinjin Peptide, namely, Trade name: Kinjin Peptide (GeneTime), General name: Recombinant Human Epidermal Growth Factor Derivative for External Use, Liquid, Manufacturer: Shenzhen Huashengyuan Genetic Engineering Development Co., Ltd. Its ingredients: The active ingredient is recombinant human epidermal growth factor (rhEGF), with 10% glycerin and 1.0% mannitol as protective agents, and the rhEGF in Kinjin Peptide promotes the synthesis of DNA, RNA and hydroxyproline during the skin and mucous membrane wound tissue repair process, and accelerates the production of wound granulation tissue and the proliferation of epithelial cells, thereby shortening the wound healing time. Kangfuxin Ye, Manufacturer: Sichuan Good Doctor Panxi Pharmaceutical Co., Ltd., is a solution of dried extract of Periplaneta americana used for wounds such as wounds, trauma, ulcers, fistulas, burns, scalds and bedsores.

[0035] Example 2 Healing effect of polypeptide on skin ulcers in db / db mice Experimental animals: diabetic modeling mice (db / db male mice), normal mice (m / m male mice), SPF grade, 8-10 weeks old, weighing 40-50g, Changzhou Cabins Laboratory Animal Co., Ltd., Experimental Animal Production Permit Certificate Number: SCXK(Su)2016-0010, Experimental Animal Use Permit Certificate Number: SYXK(Hu)2020-0038.

[0036] Experimental method: After the blood glucose level of db / db mice reached the standard (blood glucose level after 4 hours of fasting ≥ 16.7 mmol / L), the grouping test was started. According to the random grouping method, the animals were divided into 10 groups, and were divided into the normal control group, the model control group, the new recovery liquid group (40 μL / animal), and the gold peptide group (40 IU / cm 2 ), target polypeptide group (30 μg / cm 2After the mice were anesthetized by inhaling isoflurane, a circular wound of about 12 mm in diameter was cut into the full thickness of the skin on the back of the mice with a cutter, reaching the depth to the fascial layer, and the wound was photographed and the wound area was recorded as the baseline value (the day of wounding was recorded as Day 0). From the next day (Day 1), animals in each group were given drug treatment as necessary, and all were applied externally at the skin wound site. Both the normal control group and the model control group were administered 40 μL of saline, and the Kinin peptide group (40 IU / cm 2 ) were administered 40 μL of a topical solution of recombinant human epidermal growth factor (HERG) diluted with saline (Shenzhen Huashengyuan Genetic Engineering Development Co., Ltd.), and the control polypeptide group (30 μg / cm 2 ) were administered 40μL of the corresponding concentration of polypeptide solution prepared with saline once a day, and 40μL of Kangfu New Liquid (Sichuan Good Doctor Panxi Pharmaceutical Co., Ltd.) were administered twice a day. The administration was continued every day until the wound was basically healed. The skin wounds were measured and photographed twice a week, and the wound area was calculated by Image-J software to observe the wound healing status of the animals in each group. Experimental Results: The experimental results are shown in Table 4.

[0037] [Table 4]

[0038] The research results in Table 4 showed that the polypeptide had a significant promoting effect on skin wound healing in diabetic mice on the 14th day, and the effect was superior to that of the Kanfu Xin Liquid group, and the effect of the polypeptide group was equivalent to that of the Kinyin Peptide group.

[0039] Example 3 Healing effect of polypeptide on acute mechanical skin injury in rats Experimental animals: SD male rats, SPF grade, 6 weeks old, weighing 180-220g, Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., Animal Permit Certificate Number: SCXK(Kyoto)2016-0006, Qualification Certificate Number: NO.110011210104746538.

[0040] Experimental method: SPF grade SD rats were housed in clean, sterile cages, and given water and samples at regular intervals every day. The bedding was replaced and the temperature was maintained at 20-26°C and the humidity at 40%-70%. The rats were housed for one week to adapt to the environment. According to the random grouping method, the animals were divided into six groups, and were divided into a model control group (physiological saline), a gold-in-peptide group (40 IU / cm 2 , recombinant human epidermal growth factor topical solution, Shenzhen Huashengyuan Genetic Engineering Development Co., Ltd.), target polypeptide group (8 μg / cm 2 ) were divided into three groups. After anesthetizing the rats with intraperitoneal injection of 3% sodium pentobarbital, 1 cm of hair was cut off from the wound edge, the wound area was first disinfected with iodophor, and then the wound area was locally disinfected with 75% alcohol, and a circular full-thickness skin wound with a diameter of 1.5 cm was created 4 cm below the neck from the center of the line connecting the ear and back, with the spine as the midline, until it reached the depth of the muscle layer. The surrounding skin was fixed with a rubber ring of the same size to form an animal model of acute mechanical injury. After modeling, the wound of the rats was exposed and kept in a single cage. When changing drugs, the wound surface was first excised with iodophor, and the wound was washed and wiped dry with sterile saline, and the rats in each group were further administered with 40 μL of the corresponding drug solution, which was applied topically to the wound at regular intervals once a day. On days 0, 3, 7, 10, and 14 after administration, images of the wounds of the rats in each group were taken, and the wound area was calculated using image analysis software (Image J), ​​and the wound healing rate was calculated by the formula. Experimental Results: The experimental results are shown in Table 5.

[0041] [Table 5]

[0042] The research results in Table 5 showed that the polypeptide group had a significant promoting effect on wound healing after mechanical skin injury in rats on the 14th day, and the effect was obviously superior to that of the kinin peptide group.

[0043] Example 4 Promotion of HaCAT cell proliferation by polypeptide Experimental method: The concentration of human immortalized keratinocytes (HaCaT cells) was 1.0 × 10 5 ~5.0×10 5 The cells were subcultured at 37°C and 5% CO2 for 24-36 hours to detect biological activity. The cells were digested with 0.25% trypsin for 5 min, and digestion was terminated by adding 1640 whole blood medium at least 1x the trypsin volume. The cell suspension was collected and centrifuged at 1000 RPM for 3 min, the supernatant was discarded, and 2 mL of 1640 whole blood medium was added to resuspend the cells. 20uL of the cell suspension was taken and stained with AOPI. The concentration of cells in the suspension was detected using a cell counter, and a concentration of 5x10 was detected using 1640 medium with 10% serum concentration. 4 The solution was prepared to give a concentration of 100 μL / well, i.e., 5,000 cells / well, and inoculated into a 96-well cell culture plate at 100 μL / well, and cultured overnight at 37° C. and 5% CO 2 .

[0044] After 24h, the original medium was discarded, and different concentrations of polypeptide solutions prepared in 100μL of 1% serum 1640 medium were added. At the same time, an EGF control group was set up, that is, 100μL of recombinant human epidermal growth factor (EGF) solution prepared in 1% serum 1640 medium was added, the final concentration was 100ng / mL, and a model control group was set up, that is, an equal volume of 1% serum 1640 medium was added. The cells were cultured for 72h under the conditions of 37℃ and 5% CO2, and the proliferation promotion status of the HaCaT cell line was detected using the CCK8 reagent kit.

[0045] Experimental results: The experimental results are shown in Figure 1 (*: P<0.05, **: P<0.01). The research results in Figure 1 show that after 72 hours of action, the polypeptide has a significant proliferation-promoting effect on HaCaT cells (human immortalized keratinocytes), which are epithelial cells, one of the main cell types involved in the wound repair process.

[0046] Example 5 Promotion of HMEC-1 cell proliferation by polypeptides Experimental method: Human microvascular endothelial cells (HMEC-1 cells) were cultured in 10% serum medium at 37°C and 5% CO2. The drug was replaced every 1-2 days, and the cell concentration was kept at 4 × 10 6Cells were harvested and passaged at 4 × 10 cells / mL in serum-free medium. 4 The solution was adjusted to give cells / mL and inoculated into a 96-well cell culture plate at 100 uL / well, i.e., 4000 cells / well, and cultured at 37° C. and 5% CO 2 until the cells attached to the wall. Polypeptides were dissolved in PBS solution to prepare a mother solution with a concentration of 1 mg / mL. The mother solution of polypeptides was prepared in 0% serum medium to be the test concentration as the experimental group. Recombinant human vascular endothelial growth factor VEGF (100 ng / mL) was prepared in the same way and added as a positive control. An equal amount of 0% serum without drug medium was added to the blank control group, which was added in 5 parallel wells and incubated at 37°C and 5% CO2 for 48 hours. CCK-8 was used to detect the cell proliferation status, and serum-free medium containing 10% CCK-8 was added to each well. After incubation in an incubator for 2 hours, the absorbance at 450 nm was measured using a microplate reader.

[0047] Experimental Results: The experimental results are shown in Figure 2 (*: P<0.05, **: P<0.01). The research results in Figure 2 showed that the polypeptide had a significant proliferation-promoting effect on HMEC-1 cells (human microvascular endothelial cells), which are endothelial cells, one of the main cell types involved in the wound repair process.

[0048] Example 6 Promotion of Balb-3T3 cell proliferation by polypeptides Experimental method: Mouse embryonic fibroblasts (Balb-3T3 cells) were cultured in 10% serum medium at 37°C and 5% CO2. The drug was replaced every 1-2 days, and the cell concentration was kept at 4 × 10 6 Cells were harvested and subcultured at 3 × 10 cells / mL in 2.5% FBS maintenance medium. 4 The solution was adjusted to cells / mL and inoculated into a 96-well cell culture plate at 100 uL / well, i.e., 3000 cells / well, and cultured at 37° C., 5% CO 2 until the cells attached to the wall.

[0049] Polypeptides were dissolved in 2.5% FBS maintenance medium to prepare a mother solution with a concentration of 1 mg / mL. The mother solution of the polypeptides was prepared as the experimental group so that the test concentration was in 2.5% FBS maintenance medium. Recombinant human basic fibroblast growth factor FGF (50 ng / mL) and recombinant human platelet-derived growth factor PDGF-BB (30 ng / mL) were prepared in the same manner and added as positive controls. An equal amount of 2.5% FBS maintenance medium was added to the blank control group, which was added in 5 parallel wells and incubated at 37°C and 5% CO2 for 48 hours. CCK-8 was used to detect the cell proliferation status, and serum-free medium containing 10% CCK-8 was added to each well. After incubation in an incubator for 2 h, the absorbance at 450 nm was measured using a microplate reader.

[0050] Experimental Results: The experimental results are shown in Figure 3 (*: P<0.05, **: P<0.01). The research results in Figure 3 showed that the polypeptide had a significant proliferation-promoting effect on Balb-3T3 cells (mouse embryonic fibroblasts), which are one of the main cell types involved in the wound repair process.

[0051] Example 7 Effect of polypeptides on RSC96 cell proliferation Experimental method: Rat Schwann cells (RSC96 cells) were cultured at a concentration of 1.0 x 10 5 ~5.0×10 5 The cells were then cultured at 37°C and 5% CO2 for 24-36 hours to detect biological activity. The cells were digested with trypsin, harvested, and cultured in serum-free medium at a concentration of 5 × 10 4 The solution was prepared to give a total volume of 100 μL / mL, i.e., 8,000 cells / well, and inoculated into a 96-well cell culture plate at 100 μL / well, i.e., 8,000 cells / well, and cultured overnight at 37° C. and 5% CO2.

[0052] Polypeptide was dissolved in PBS solution to prepare a mother solution with a concentration of 400ug / ml, and the mother solution of polypeptide was prepared in 0% serum medium to obtain the test concentration as the experimental group, and an equal amount of 0% serum without drug medium was added to the control group, which was added in 4 parallel wells and incubated at 37℃ and 5% CO2 for 48 hours. CCK-8 was used to detect the cell proliferation status, and the old medium was removed, and serum-free medium containing 10% CCK-8 was added to each well, and after incubation in an incubator for 2h, the absorbance at 450nm was measured using a microplate reader. Experimental results: The experimental results are shown in Figure 4 (*: P<0.05, **: P<0.01). The research results in Figure 4 showed that the polypeptide had a significant proliferation-promoting effect on RSC96 cells.

[0053] Example 8 Promotion of tissue regeneration in zebrafish by polypeptides Experimental animals: wild-type AB strain zebrafish, reared in fish culture water at 28°C (water quality: reverse osmosis water with 200 mg instant sea salt per 1 L, conductivity 450-550 μS / cm, pH 6.5-8.5, hardness 50-100 mg / L CaCO3), aged 3 days post-fertilization (dpf), bred and provided by the Fish Breeding Center of Hangzhou Huante Biotechnology Co., Ltd., with the Experimental Animal Use Permit Certificate Number: SYXK (Zhejiang) 2012-0171, and breeding management met the requirements of the international AAALAC certification (certification number: 001458).

[0054] Experimental method: 3 dpf wild-type AB strain zebrafish were randomly selected, and the caudal fins of the zebrafish were removed to establish a zebrafish caudal fin injury model. The model zebrafish were randomly distributed in a 6-well plate, and 30 zebrafish were placed in each well (each experimental group). Different concentrations of polypeptides were dissolved in water and administered (final concentrations of 250, 500, and 1000 μg / mL), and a normal control group (zebrafish caudal fin uninjured) and a model control group were simultaneously set up, with a volume of 3 mL per well. After treatment at 28 °C for 3 days, 10 zebrafish were randomly selected from each experimental group and placed under a dissecting microscope to take pictures, and the data were collected and analyzed using the advanced image processing software NIS-Elements D 3.20 to analyze the regenerated area of ​​the zebrafish caudal fin, and the statistical analysis results of the indicators were used to evaluate the promotion effect of the samples on tissue regeneration. Experimental results: The experimental results are shown in Figure 5 (compared with the model control group, *: P<0.05, **: P<0.01). The research results showed that the polypeptide had a significant promoting effect on zebrafish tissue regeneration.

[0055] Example 9 Promotion of vascular regeneration in zebrafish by polypeptides Experimental animals: vascular green fluorescent transgenic zebrafish, reared in fish culture water at 28℃ (water quality: reverse osmosis water with 200mg instant sea salt added per 1L, conductivity 450-550μS / cm, pH 6.5-8.5, hardness 50-100mg / L CaCO3), aged 1 day post-fertilization (dpf), bred and provided by the Fish Breeding Center of Hangzhou Huante Biotechnology Co., Ltd., with the Experimental Animal Use Permit Certificate Number: SYXK(Zhejiang)2012-0171, and breeding management met the requirements of the international AAALAC certification (Certification Number: 001458).

[0056] Experimental method: 1 dpf vascular green fluorescent transgenic zebrafish were randomly selected and placed in a 6-well plate with 30 fish per well (each experimental group). The zebrafish were treated with standard dilution water for the normal control group, and 60 nM simvastatin was dissolved in water and administered to each of the remaining experimental groups for 3 h induction to establish the zebrafish microvascular defect model, with the volume of each well being 3 mL. After 3 h, the simvastatin induction was terminated. Then, the aqueous solution of the positive control group was replaced with 5.90 μg / mL astragaloside IV, and the aqueous solution of each of the remaining groups was replaced with standard dilution water, with the volume of each well being 3 mL. The polypeptide was intravenously injected into the test drug groups at different doses, i.e., concentrations of 12.5, 25.0, and 50.0 mg / mL, respectively, with an injection volume of 10 nL. After treatment at 28°C for 2 days, 10 zebrafish were randomly selected from each experimental group, placed under a fluorescent microscope to take pictures, and analyzed using the advanced image processing software NIS-Elements D 3.20 to collect data. The area of ​​intestinal vascular tissue and the number of intestinal vascular branches were analyzed, and the statistical analysis results of these indicators were used to evaluate the effect of the samples in promoting vascular regeneration.

[0057] Experimental results: The experimental results are shown in Figures 6 and 7 (compared to the model control group, *: P<0.05, **: P<0.01). The research results showed that the polypeptide could significantly promote the increase in the area of ​​the intestinal blood vessels of zebrafish and the increase in the number of intestinal blood vessel branches, and had the effect of promoting vascular regeneration.

[0058] Example 10: Healing effect of polypeptide on skin ulcers in streptozotocin (STZ)-induced diabetic rats Experimental animals: SPF grade, healthy male SD rats (body weight 180–200 g) were fed a high-fat, high-carbohydrate diet for 2 weeks, then fasted for 6 h. Each rat was then administered STZ solution (50 mg kg -1 ) was rapidly injected intraperitoneally once, and if the random blood glucose level was >16.7 mmol / L 48 h later, the rat model of type 2 diabetes was considered to be successfully modeled. The experimental animals were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., with the experimental animal quality certificate number SCXK (Kyoto) 2017-0033 and the experimental animal use permission certificate: SCXK (Kyoto) 2017-0033.

[0059] Experimental method: 90 diabetic rats were selected, 15 in each group, and each group was divided into a model control group (saline), a high-dose polypeptide group (30 μg / cm 2 ), medium dose polypeptide group (10 μg / cm 2 ), low-dose polypeptide group (3 μg / cm 2 ), Kinin peptide group (40IU / cm 2 , recombinant human epidermal growth factor topical solution, Shenzhen Huashengyuan Genetic Engineering Development Co., Ltd.), New Recovery Solution Group (36μL / cm 2 The rats were anesthetized by intraperitoneal injection of 2% sodium pentobarbital (0.2 mL / 100 g), and then anesthetized with 2 cm punctures on both sides of the spinal column. 2 A full-thickness skin defect wound was prepared, and a rubber ring with a diameter of 2.3 cm was added to the outer edge of the wound. After wound hemostasis, topical drug treatment was performed according to group. Except for the recovery liquid group, the solution was administered twice a day, and the other groups were administered once a day, with the administration volume being 72 μL per wound for 14 consecutive days. After administration to the wound, the wound was covered with sterile Vaseline gauze (5 cm × 5 cm) and wrapped with multiple layers of sterile gauze. After wound surgery, the wound was photographed and the wound area was recorded as the baseline value (the day of wounding was recorded as Day 0). During the administration period, the wound area was photographed and measured three times a week, and the granulation tissue growth and healing status of the wounds in each group were observed daily.

[0060] The experimental results are shown in Table 6 and Figure 8 (Note: compared with the model control group, *: P<0.05, **: P<0.01). As can be seen from Table 6, on day 10, the healing rates of the low-dose and medium-dose polypeptide groups are slightly higher than that of the model control group, and the low-dose and medium-dose polypeptides have a tendency to promote wound healing in diabetic rats. In the entire wound healing process, the healing rates of the high-dose polypeptide group are all higher, and on day 10, the healing rates are significantly higher than those of the model control group and slightly higher than those of the gold peptide group. On days 7 to 12, the healing rates are slightly higher than those of the revitalization liquid group, showing that the high-dose polypeptide group has a significant promoting effect on wound healing in diabetic rats, and its effect in this experiment is slightly better than that of the gold peptide. As can be seen from Figure 8, the promotion of the new granulation tissue growth rate by the low-dose, medium-dose, and high-dose polypeptide groups all have significant differences compared to the model control group. Therefore, the polypeptide has a promoting effect on new granulation tissue growth and wound healing in STZ-induced diabetic rat wounds.

[0061] [Table 6]

[0062] Example 11 Healing effect of polypeptide on SD rat total cortical defect wound Experimental animals: SD male rats, SPF grade, 6 weeks old, weighing 180-220g, Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., Experimental Animal Quality Approval Certificate Number: NO.110011220109610345, Experimental Animal Use Permit Certificate: SCXK(Kyoto)2021-0011. Experimental method: SD rats were randomly divided into groups according to weight, with 8 animals per group, and were divided into a solvent group, a polypeptide group (50 μg / cm 2 ), comparative polypeptide group 1 (41.90 μg / cm 2 ), comparative polypeptide group 2 (52.66 μg / cm 2 The amino acid sequence of comparative polypeptide 1 was Glu-Pro-Val-Pro-Leu, and the amino acid sequence of comparative polypeptide 2 was Pro-Ala-Ala-Glu-Pro-Val-Pro-Leu-Val-Lys-Gln-Glu.

[0063] Each experimental rat was anesthetized by intraperitoneal injection of 2% sodium pentobarbital (0.2 mL / 100 g), and then one 2 cm incision was made on each side of the dorsal spine. 2 Cortical total defect wounds were prepared in each group. After hemostasis of the wounds, the corresponding drugs were administered locally to the wounds according to group. Each group was administered once a day, with the administration volume being 72μL / wound each time, for 14 consecutive days. After administration to the wounds, the wounds were covered with sterile Vaseline gauze (5cm×5cm) and wrapped in multiple layers of sterile gauze. After wound surgery, the wounds were photographed and the wound area was recorded as the baseline value (the day of wounding was recorded as Day 0), and the wound area was photographed and measured three times a week during the administration period to observe the healing status. Experimental Results: The experimental results are shown in Table 7.

[0064] [Table 7]

[0065] The research results showed that the polypeptide group of the present invention (50 μg / cm 2 ) had a high and significantly different healing rate on the 3rd to 10th day after surgery, and the healing effects of the polypeptide of the present invention were superior to those of the comparative polypeptide 1 group and the comparative polypeptide 2 group.

[0066] In summary, the polypeptide according to the present invention, compared with recombinant human epidermal growth factor commonly used in the treatment of skin injury diseases in the prior art, not only has obvious wound healing promoting effect on skin ulcers and injuries, especially chronic intractable wounds on the body surface, such as diabetic foot ulcers, decubitus ulcers, vascular ulcers and infectious ulcers, acute and / or chronic skin diseases, diabetic foot ulcers, etc., but also has a shorter peptide chain, which allows faster and better dermal absorption, excellent stability both in vivo and in vitro, and significant proliferation promoting effect on human immortalized keratinocytes, human microvascular endothelial cells, fibroblasts, glial cells, and tissue and vascular regeneration. The polypeptide according to the present invention can be applied to the manufacture of products for preventing or treating skin injury diseases, and can exert positive treatment and repair effects.

[0067] Although the present invention discloses the above examples, the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the present invention are equivalent replacement methods, and all are included in the scope of the claims of the present invention.

Claims

1. The use of a polypeptide in the manufacture of a product for preventing or treating a skin damage disease, comprising: The polypeptide is Pro-Ala-Ala-Glu-Pro-Val-Pro-Leu or a physiologically compatible salt thereof.

16. An application characterized in that

2. The skin damage disease includes wounds, ulcers, dermatitis, eczema, urticaria, polymorphous light eruption, herpes, acne, impetigo, melasma, vitiligo, lupus erythematosus, dermatomyositis, scleroderma, folliculitis, scabies, onychomycosis, chickenpox, infantile rash, warts, carbuncles, boils or ringworm; 2. The application according to claim 1 .

3. The dermatitis includes atopic dermatitis, contact dermatitis, neurodermatitis, seborrheic dermatitis, hormone-dependent dermatitis, or stasis dermatitis.

3. The application according to claim 2 .

4. The wound includes a chronic non-healing wound on the surface of the body; 3. The application according to claim 2 .

5. The chronic intractable wound on the body surface includes a diabetic foot ulcer, a pressure ulcer, a vascular ulcer, or an infectious ulcer; 5. The application according to claim 4.

6. The product comprises a drug, a skin care product or a cosmetic product.

2. The application according to claim 1 .

7. The product is a topical formulation.

2. The application according to claim 1 .

8. The topical preparations include solutions, emulsions, gels, emulsions, creams, gels, sprays, masks or dressings; 8. The application according to claim 7 .

9. The polypeptide has a proliferation-promoting effect on human immortalized keratinocytes, human microvascular endothelial cells, fibroblasts, glial cells, and tissue and / or vascular regeneration, thereby healing wounds; 8. The application according to claim 7 .

Citation Information

Patent Citations

  • Therapeutic agent for intractable skin deficiency wound

    JP1996073373A

  • Polypeptides for repairing mucosal damage or skin wounds and uses thereof

    JP2023531282A

  • Novel polypeptide having angiogenesis-inducing activity and antibacterial activity, and use thereof for medical purposes

    WO2010061915A1